creatine has been researched along with Acute Confusional Senile Dementia in 111 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 9.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 9.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 7.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "Creatine deposits were found in all TgCRND8 mice; the extent of deposition increased with age." | 5.36 | Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. ( Agrawal, V; Del Bigio, MR; Gallant, M; Gough, KM; Julian, R; Kastyak, M; Kuzyk, A; Rak, M; Sivakumar, G; Westaway, D, 2010) |
| "Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD)." | 5.14 | Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. ( Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL, 2010) |
| "The purpose of this study was to measure metabolite level changes in patients with newly diagnosed Alzheimer Disease (AD) following four months of donepezil treatment." | 5.13 | High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. ( Bartha, R; Borrie, MJ; Rupsingh, R; Rylett, J; Smith, M; Wells, JL, 2008) |
| "In this proton magnetic resonance spectroscopy ((1)H-MRS) study, the authors correlated cognitive improvement after 3 months of treatment with donepezil with changes of N-acetylaspartate (NAA) level and NAA/Creatine (Cr) ratio in the medial temporal and parietal lobe of 17 patients with Alzheimer disease." | 3.73 | Treatment monitoring and response prediction with proton MR spectroscopy in AD. ( Block, W; Freymann, K; Jessen, F; Maier, W; Schild, HH; Traeber, F, 2006) |
| "In this study, cognitively intact chronic hypertensive older patients had a higher white matter myoinositol/creatine ratio compared with healthy older subjects, suggesting that myoinositol may be a sensitive marker of the effects of chronic hypertension on the brain." | 3.71 | Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease. ( Benedetti, C; Catani, M; Cherubini, A; Howard, R; Mariani, E; Mecocci, P; Metastasio, A; Pelliccioli, GP; Senin, U; Tarducci, R, 2002) |
| " Although changes in myo-inositol and creatine occur in the early stages of AD, abnormalities of N-acetyl aspartate do not occur in mild AD but progressively change with dementia severity." | 3.71 | Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. ( Alexander, GE; Chang, L; Huang, W; Krasuski, JS; Rapoport, SI; Schapiro, MB; Shetty, HU, 2001) |
| "The purpose of this study was to determine cerebral myo-inositol (mI) in adults with Down syndrome (DS), and to trace the chronobiology of DS to Alzheimer disease (AD)." | 3.69 | Role of increased cerebral myo-inositol in the dementia of Down syndrome. ( Ross, BD; Shonk, T, 1995) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "Patients with mild to moderate Alzheimer's disease received placebo or xanomeline for 6 months." | 2.68 | Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. ( Bodick, N; Offen, WW; Renshaw, PF; Satlin, A, 1997) |
| "Disease progression was investigated at 4 time points, from 9 to 18 months of age, and in 4 regions: cortex, hippocampus, striatum, and thalamus." | 1.72 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022) |
| "Detecting Alzheimer's disease (AD) at an early stage brings a lot of benefits including disease management and actions to slow the progression of the disease." | 1.62 | Early detection of Alzheimer's disease using creatine chemical exchange saturation transfer magnetic resonance imaging. ( Chen, L; Duan, W; Li, T; Lu, H; van Zijl, PCM; Wei, Z; Wong, PC; Xu, J, 2021) |
| "Amnestic mild cognitive impairment (aMCI) is often the prodromal stage to AD." | 1.43 | (1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease. ( Chen, W; Chen, X; Guo, Z; Hou, H; Liu, X; Shen, Y; Wei, F, 2016) |
| "Bioenergetic failure is a feature of Alzheimer's disease (AD)." | 1.40 | Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease. ( Bazinet, RP; Francis, BM; Gupta, S; Maj, M; Mount, HT; Robinson, B; Song, BJ; Yang, J, 2014) |
| "Increasing evidence suggest that Alzheimer's disease (AD) is a heterogeneous disorder that includes several subtypes with different etiology and progression." | 1.40 | Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease. ( Cedazo-Mínguez, Á; Cifuentes, A; Ibáñez, C; Lodeiro, M; Simó, C, 2014) |
| "Agitation and depression are among the commonest behavioural and psychological symptoms exhibited by Alzheimer's disease patients." | 1.39 | Differences in brain metabolism associated with agitation and depression in Alzheimer's disease. ( Fuh, JL; Hung, CW; Lirng, JF; Tsai, CF; Wang, SJ, 2013) |
| "Myo-inositol (mIns) is a marker of glial cells proliferation and has been shown to increase in early Alzheimer's disease (AD) pathology." | 1.39 | MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease. ( Cai, K; Crescenzi, R; Hariharan, H; Haris, M; Kogan, F; Nath, K; Reddy, R; Singh, A, 2013) |
| "Murine models of Alzheimer's disease (AD) provide means to detect and follow biomarker changes similar to those observed in humans." | 1.38 | Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1). ( Alquézar, C; Antequera, D; Barrios, L; Bartolomé, F; Carro, E; Cerdán, S; Esteras, N; Martín-Requero, A, 2012) |
| "The diagnosis of mild or questionable Alzheimer's disease (AD) depends on clinical criteria that often leave a margin for doubt." | 1.37 | Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. ( Andreiuolo, PA; Bottino, CM; de Oliveira-Souza, R; Moll, J; Silveira de Souza, A; Tovar-Moll, F, 2011) |
| "Amnestic mild cognitive impairment (MCI) is highly predictive of Alzheimer's disease but the pace of deterioration varies across patients." | 1.37 | Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment. ( Fayed, N; Modrego, PJ, 2011) |
| "Creatine deposits were found in all TgCRND8 mice; the extent of deposition increased with age." | 1.36 | Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease. ( Agrawal, V; Del Bigio, MR; Gallant, M; Gough, KM; Julian, R; Kastyak, M; Kuzyk, A; Rak, M; Sivakumar, G; Westaway, D, 2010) |
| "The cognitive decline in Alzheimer's disease (AD) patients has been reported to involve alterations in the medial temporal lobe and the posterior cingulate gyrus." | 1.34 | A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease. ( Horiguchi, J; Inagaki, T; Inami, Y; Kawamukai, T; Miyaoka, T; Okazaki, S; Shinno, H; Utani, E, 2007) |
| "Given the available therapies for Alzheimer's disease, early diagnosis is of paramount importance." | 1.33 | Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. ( Fayed, N; Modrego, PJ; Pina, MA, 2005) |
| "Disease-specific metabolic changes in Alzheimer's disease and frontotemporal dementia/Pick complex were examined by proton magnetic resonance spectroscopy at 3." | 1.33 | Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex. ( Abe, K; Hattori, N; Mihara, M; Sakoda, S; Sawada, T, 2006) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| "To investigate metabolic changes in Alzheimer's disease (AD), we performed proton MR spectroscopy at 3T Spectra were acquired from the gray matter of the posterior cingulate gyrus and the precuneus, and from the parietooccipital white matter in nine AD patients and 12 controls." | 1.31 | Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. ( Abe, K; Hattori, N; Sakoda, S; Sawada, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (17.12) | 18.2507 |
| 2000's | 40 (36.04) | 29.6817 |
| 2010's | 42 (37.84) | 24.3611 |
| 2020's | 10 (9.01) | 2.80 |
| Authors | Studies |
|---|---|
| Hone-Blanchet, A | 1 |
| Bohsali, A | 1 |
| Krishnamurthy, LC | 1 |
| Shahid, S | 1 |
| Lin, Q | 1 |
| Zhao, L | 1 |
| Loring, D | 1 |
| Goldstein, F | 1 |
| John, SE | 1 |
| Fleischer, CC | 1 |
| Levey, A | 1 |
| Lah, J | 1 |
| Qiu, D | 1 |
| Crosson, B | 1 |
| Shad, KF | 1 |
| Soubra, W | 1 |
| Cordato, DJ | 1 |
| Gozdas, E | 1 |
| Hinkley, L | 1 |
| Fingerhut, H | 1 |
| Dacorro, L | 1 |
| Gu, M | 1 |
| Sacchet, MD | 1 |
| Hurd, R | 1 |
| Hosseini, SMH | 1 |
| Muñoz-Moreno, E | 1 |
| Simões, RV | 1 |
| Tudela, R | 1 |
| López-Gil, X | 1 |
| Soria, G | 1 |
| Lyros, E | 1 |
| Ragoschke-Schumm, A | 1 |
| Kostopoulos, P | 1 |
| Sehr, A | 1 |
| Backens, M | 1 |
| Kalampokini, S | 1 |
| Decker, Y | 1 |
| Lesmeister, M | 1 |
| Liu, Y | 2 |
| Reith, W | 1 |
| Fassbender, K | 1 |
| Peña-Bautista, C | 1 |
| Torres-Cuevas, I | 1 |
| Baquero, M | 1 |
| Ferrer, I | 1 |
| García, L | 1 |
| Vento, M | 1 |
| Cháfer-Pericás, C | 1 |
| Snow, WM | 1 |
| Cadonic, C | 1 |
| Cortes-Perez, C | 1 |
| Adlimoghaddam, A | 1 |
| Roy Chowdhury, SK | 1 |
| Thomson, E | 1 |
| Anozie, A | 1 |
| Bernstein, MJ | 1 |
| Gough, K | 1 |
| Fernyhough, P | 1 |
| Suh, M | 1 |
| Albensi, BC | 1 |
| Roschel, H | 1 |
| Gualano, B | 1 |
| Ostojic, SM | 1 |
| Rawson, ES | 1 |
| Müller, L | 1 |
| Power Guerra, N | 1 |
| Stenzel, J | 1 |
| Rühlmann, C | 2 |
| Lindner, T | 2 |
| Krause, BJ | 2 |
| Vollmar, B | 2 |
| Teipel, S | 1 |
| Kuhla, A | 2 |
| Chen, L | 1 |
| van Zijl, PCM | 1 |
| Wei, Z | 1 |
| Lu, H | 1 |
| Duan, W | 1 |
| Wong, PC | 1 |
| Li, T | 1 |
| Xu, J | 1 |
| Regenold, WT | 1 |
| Blumenthal, JB | 1 |
| Loreck, DJ | 1 |
| Mordecai, KL | 1 |
| Scarinzi, G | 1 |
| Doddi, SR | 1 |
| Adler, L | 1 |
| Polei, S | 1 |
| Hadlich, S | 1 |
| Teipel, SJ | 1 |
| Zhang, W | 2 |
| Gu, GJ | 1 |
| Zhang, Q | 1 |
| Liu, JH | 1 |
| Zhang, B | 1 |
| Guo, Y | 1 |
| Wang, MY | 1 |
| Gong, QY | 1 |
| Xu, JR | 1 |
| Yeh, YC | 2 |
| Li, CW | 2 |
| Kuo, YT | 2 |
| Huang, MF | 2 |
| Liu, TL | 2 |
| Jaw, TS | 1 |
| Yang, YH | 1 |
| Kuo, KC | 1 |
| Chen, CS | 2 |
| Joe, E | 1 |
| Medina, LD | 1 |
| Ringman, JM | 1 |
| O'Neill, J | 1 |
| Cleeland, C | 1 |
| Pipingas, A | 1 |
| Scholey, A | 1 |
| White, D | 1 |
| Ito, S | 1 |
| Gasparovic, C | 1 |
| Prestopnik, J | 1 |
| Thompson, J | 1 |
| Taheri, S | 1 |
| Huisa, B | 1 |
| Schrader, R | 1 |
| Adair, JC | 1 |
| Rosenberg, GA | 2 |
| Kantarci, K | 6 |
| Bittner, DM | 1 |
| Heinze, HJ | 1 |
| Kaufmann, J | 1 |
| Tsai, CF | 1 |
| Hung, CW | 1 |
| Lirng, JF | 1 |
| Wang, SJ | 1 |
| Fuh, JL | 1 |
| Francis, BM | 1 |
| Yang, J | 2 |
| Song, BJ | 1 |
| Gupta, S | 1 |
| Maj, M | 1 |
| Bazinet, RP | 1 |
| Robinson, B | 1 |
| Mount, HT | 1 |
| Yen, CF | 1 |
| Chen, CH | 1 |
| Lee, CC | 1 |
| Liu, GC | 1 |
| Graff-Radford, J | 1 |
| Boeve, BF | 5 |
| Murray, ME | 1 |
| Ferman, TJ | 2 |
| Tosakulwong, N | 1 |
| Lesnick, TG | 1 |
| Maroney-Smith, M | 1 |
| Senjem, ML | 1 |
| Gunter, J | 2 |
| Smith, GE | 5 |
| Knopman, DS | 4 |
| Jack, CR | 5 |
| Dickson, DW | 1 |
| Petersen, RC | 5 |
| Lodeiro, M | 1 |
| Ibáñez, C | 1 |
| Cifuentes, A | 1 |
| Simó, C | 1 |
| Cedazo-Mínguez, Á | 1 |
| Suriyajakryuththana, W | 1 |
| Tuntiyatorn, L | 1 |
| Teepprasarn, N | 1 |
| Sukying, C | 1 |
| Zou, JX | 1 |
| Wang, MJ | 1 |
| Lei, XJ | 1 |
| Chen, XG | 1 |
| Penner, J | 2 |
| Wells, JL | 4 |
| Borrie, MJ | 3 |
| Woolmore-Goodwin, SM | 1 |
| Bartha, R | 4 |
| Doert, A | 1 |
| Pilatus, U | 2 |
| Zanella, F | 1 |
| Müller, WE | 1 |
| Eckert, GP | 1 |
| Calderón-Garcidueñas, L | 1 |
| Mora-Tiscareño, A | 1 |
| Melo-Sánchez, G | 1 |
| Rodríguez-Díaz, J | 1 |
| Torres-Jardón, R | 1 |
| Styner, M | 1 |
| Mukherjee, PS | 1 |
| Lin, W | 1 |
| Jewells, V | 1 |
| Wang, H | 1 |
| Tan, L | 1 |
| Wang, HF | 1 |
| Yin, RH | 1 |
| Wang, WY | 1 |
| Chang, XL | 1 |
| Jiang, T | 1 |
| Yu, JT | 1 |
| Guo, Z | 2 |
| Zhang, J | 1 |
| Liu, X | 2 |
| Hou, H | 2 |
| Cao, Y | 1 |
| Wei, F | 2 |
| Li, J | 1 |
| Chen, X | 2 |
| Shen, Y | 2 |
| Chen, W | 2 |
| Su, L | 1 |
| Blamire, AM | 1 |
| Watson, R | 1 |
| He, J | 1 |
| Hayes, L | 1 |
| O'Brien, JT | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Watanabe, T | 1 |
| Shiino, A | 2 |
| Akiguchi, I | 2 |
| Griffith, HR | 2 |
| den Hollander, JA | 2 |
| Okonkwo, OC | 1 |
| O'Brien, T | 1 |
| Watts, RL | 1 |
| Marson, DC | 2 |
| Wang, Z | 1 |
| Zhao, C | 1 |
| Yu, L | 1 |
| Zhou, W | 1 |
| Li, K | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 1 |
| Pantel, J | 1 |
| Rupsingh, R | 3 |
| Borrie, M | 1 |
| Smith, M | 3 |
| Kuzyk, A | 1 |
| Kastyak, M | 1 |
| Agrawal, V | 1 |
| Gallant, M | 2 |
| Sivakumar, G | 1 |
| Rak, M | 2 |
| Del Bigio, MR | 2 |
| Westaway, D | 2 |
| Julian, R | 2 |
| Gough, KM | 2 |
| Xu, W | 1 |
| Zhan, Y | 1 |
| Huang, W | 2 |
| Wang, X | 1 |
| Zhang, S | 1 |
| Lei, H | 1 |
| Foy, CM | 1 |
| Daly, EM | 1 |
| Glover, A | 1 |
| O'Gorman, R | 1 |
| Simmons, A | 1 |
| Murphy, DG | 1 |
| Lovestone, S | 1 |
| Wang, T | 1 |
| Xiao, S | 1 |
| Li, X | 1 |
| Ding, B | 1 |
| Ling, H | 1 |
| Chen, K | 1 |
| Fang, Y | 1 |
| Fayed, N | 3 |
| Modrego, PJ | 3 |
| Rojas-Salinas, G | 1 |
| Aguilar, K | 1 |
| Ashford, JW | 1 |
| Adamson, M | 1 |
| Beale, T | 1 |
| La, D | 1 |
| Hernandez, B | 1 |
| Noda, A | 1 |
| Rosen, A | 1 |
| O'Hara, R | 1 |
| Fairchild, JK | 1 |
| Spielman, D | 2 |
| Yesavage, JA | 1 |
| Silveira de Souza, A | 1 |
| de Oliveira-Souza, R | 1 |
| Moll, J | 1 |
| Tovar-Moll, F | 1 |
| Andreiuolo, PA | 1 |
| Bottino, CM | 3 |
| Esteras, N | 1 |
| Alquézar, C | 1 |
| Bartolomé, F | 1 |
| Antequera, D | 1 |
| Barrios, L | 1 |
| Carro, E | 1 |
| Cerdán, S | 1 |
| Martín-Requero, A | 1 |
| Lim, TS | 2 |
| Hong, YH | 2 |
| Choi, JY | 2 |
| Kim, HS | 2 |
| Moon, SY | 2 |
| Lee, HY | 1 |
| Chen, SQ | 1 |
| Cai, Q | 1 |
| Shen, YY | 1 |
| Wang, PJ | 1 |
| Teng, GJ | 1 |
| Zang, FC | 1 |
| Nilsen, LH | 1 |
| Melø, TM | 1 |
| Saether, O | 1 |
| Witter, MP | 1 |
| Sonnewald, U | 1 |
| Haris, M | 1 |
| Singh, A | 1 |
| Cai, K | 1 |
| Nath, K | 1 |
| Crescenzi, R | 1 |
| Kogan, F | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| van Duijn, S | 1 |
| Nabuurs, RJ | 1 |
| van Duinen, SG | 1 |
| Natté, R | 1 |
| van Buchem, MA | 1 |
| Alia, A | 1 |
| Zhong, XM | 1 |
| Hou, L | 1 |
| Luo, XN | 1 |
| Shi, HS | 1 |
| Hu, GY | 1 |
| He, HB | 1 |
| Chen, XR | 1 |
| Zheng, D | 1 |
| Zhang, YF | 1 |
| Tan, Y | 1 |
| Liu, XJ | 1 |
| Mu, N | 1 |
| Chen, JP | 1 |
| Ning, YP | 1 |
| Catani, M | 3 |
| Mecocci, P | 3 |
| Tarducci, R | 3 |
| Howard, R | 2 |
| Pelliccioli, GP | 2 |
| Mariani, E | 1 |
| Metastasio, A | 1 |
| Benedetti, C | 1 |
| Senin, U | 3 |
| Cherubini, A | 3 |
| Cheng, LL | 1 |
| Newell, K | 1 |
| Mallory, AE | 1 |
| Hyman, BT | 1 |
| Gonzalez, RG | 1 |
| Piccirilli, M | 2 |
| Sciarma, T | 1 |
| Gobbi, G | 2 |
| Pelliccioli, G | 1 |
| Petrillo, SM | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Reynolds, G | 1 |
| Edland, SD | 2 |
| Ivnik, RJ | 4 |
| Tangalos, EG | 4 |
| Kizu, O | 1 |
| Yamada, K | 1 |
| Ito, H | 1 |
| Nishimura, T | 1 |
| Assini, A | 1 |
| Cammarata, S | 1 |
| Vitali, A | 1 |
| Colucci, M | 1 |
| Giliberto, L | 1 |
| Borghi, R | 1 |
| Inglese, ML | 1 |
| Volpe, S | 1 |
| Ratto, S | 1 |
| Dagna-Bricarelli, F | 1 |
| Baldo, C | 1 |
| Argusti, A | 1 |
| Odetti, P | 1 |
| Piccini, A | 1 |
| Tabaton, M | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 3 |
| Weigand, SD | 2 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 2 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 2 |
| Hancu, I | 1 |
| Zimmerman, EA | 1 |
| Sailasuta, N | 1 |
| Hurd, RE | 1 |
| Pina, MA | 1 |
| Maestú, F | 2 |
| García-Segura, J | 1 |
| Ortiz, T | 2 |
| Montoya, J | 2 |
| Fernández, A | 2 |
| Gil-Gregorio, P | 2 |
| Campo, P | 2 |
| Fernández, S | 1 |
| Viaño, J | 2 |
| Portera, A | 1 |
| García-Segura, JM | 1 |
| Jessen, F | 4 |
| Traeber, F | 2 |
| Freymann, N | 1 |
| Maier, W | 2 |
| Schild, HH | 4 |
| Heun, R | 4 |
| Block, W | 5 |
| Engelhardt, E | 2 |
| Moreira, DM | 2 |
| Laks, J | 2 |
| Cavalcanti, JL | 1 |
| Szeghalmi, A | 1 |
| Azevedo, D | 2 |
| Tatsch, M | 2 |
| Hototian, SR | 2 |
| Bazzarella, MC | 2 |
| Castro, CC | 2 |
| Mihara, M | 1 |
| Hattori, N | 2 |
| Abe, K | 2 |
| Sakoda, S | 2 |
| Sawada, T | 2 |
| Reyes, D | 1 |
| Shiung, M | 1 |
| Freymann, K | 1 |
| Hu, L | 1 |
| Yue, Y | 1 |
| Zuo, PP | 1 |
| Jin, ZY | 1 |
| Feng, F | 1 |
| You, H | 1 |
| Li, ML | 1 |
| Ge, QS | 1 |
| Stewart, CC | 1 |
| Evanochko, WT | 1 |
| Buchthal, SD | 1 |
| Harrell, LE | 1 |
| Zamrini, EY | 1 |
| Brockington, JC | 1 |
| Shinno, H | 1 |
| Inagaki, T | 1 |
| Miyaoka, T | 1 |
| Okazaki, S | 1 |
| Kawamukai, T | 1 |
| Utani, E | 1 |
| Inami, Y | 1 |
| Horiguchi, J | 1 |
| Rami, L | 1 |
| Gómez-Ansón, B | 1 |
| Bosch, B | 1 |
| Sánchez-Valle, R | 1 |
| Monte, GC | 1 |
| Villar, A | 1 |
| Molinuevo, JL | 1 |
| Okada, T | 1 |
| Sakamoto, S | 1 |
| Nakamoto, Y | 1 |
| Kohara, N | 1 |
| Senda, M | 1 |
| Rylett, J | 1 |
| Constans, JM | 3 |
| Meyerhoff, DJ | 4 |
| Gerson, J | 1 |
| MacKay, S | 3 |
| Norman, D | 4 |
| Fein, G | 4 |
| Weiner, MW | 4 |
| Träber, F | 3 |
| Kuhl, CK | 1 |
| Fric, M | 1 |
| Keller, E | 3 |
| Lamerichs, R | 3 |
| Rink, H | 1 |
| Möller, HJ | 1 |
| Shonk, T | 3 |
| Ross, BD | 3 |
| Christiansen, P | 1 |
| Schlosser, A | 1 |
| Henriksen, O | 1 |
| Resnick, SM | 1 |
| Costa, PT | 1 |
| Shonk, TK | 1 |
| Moats, RA | 3 |
| Gifford, P | 1 |
| Michaelis, T | 1 |
| Mandigo, JC | 1 |
| Izumi, J | 1 |
| Van Dyke, C | 1 |
| Matsuda, M | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Handa, J | 1 |
| Miller, BL | 1 |
| Ernst, T | 1 |
| Woolley, S | 1 |
| Kattapong, VJ | 1 |
| Brooks, WM | 1 |
| Wesley, MH | 1 |
| Kodituwakku, PW | 1 |
| Schlegel, S | 1 |
| Graf-Morgenstern, M | 1 |
| Tintera, J | 1 |
| Gawehn, J | 1 |
| Stoeter, P | 1 |
| Bodick, N | 1 |
| Offen, WW | 1 |
| Schuff, N | 1 |
| Amend, DL | 1 |
| Tanabe, JL | 1 |
| Laubenberger, J | 1 |
| Bayer, S | 1 |
| Thiel, T | 1 |
| Hennig, J | 1 |
| Langer, M | 1 |
| Lazeyras, F | 1 |
| Charles, HC | 1 |
| Tupler, LA | 1 |
| Erickson, R | 1 |
| Boyko, OB | 1 |
| Krishnan, KR | 1 |
| Pfefferbaum, A | 1 |
| Adalsteinsson, E | 1 |
| Sullivan, EV | 1 |
| Lim, KO | 1 |
| David, SS | 1 |
| Haley, BE | 1 |
| Xu, YC | 1 |
| Campeau, NG | 1 |
| Kokmen, E | 1 |
| Alexander, GE | 1 |
| Chang, L | 1 |
| Shetty, HU | 1 |
| Krasuski, JS | 1 |
| Rapoport, SI | 1 |
| Schapiro, MB | 1 |
| Flacke, S | 2 |
| Marinho, VM | 1 |
| Rozenthal, M | 1 |
| Oliveira, AC | 1 |
| Murata, T | 1 |
| Kimura, H | 1 |
| Omori, M | 1 |
| Kado, H | 1 |
| Kosaka, H | 1 |
| Iidaka, T | 1 |
| Itoh, H | 1 |
| Wada, Y | 1 |
| Manka, C | 1 |
| Schild, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol[NCT05562232] | 45 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.[NCT05753228] | 90 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
6 reviews available for creatine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Creatine Supplementation and Brain Health.
Topics: Aging; Alzheimer Disease; Blood-Brain Barrier; Brain; Brain Concussion; Brain Injuries; Cognition; C | 2021 |
Neurochemical changes in the aging brain: A systematic review.
Topics: Aging; Alzheimer Disease; Animals; Brain; Choline; Cognition; Creatine; Humans | 2019 |
[Elucidation of Disease Mechanisms Based on Transport Function at Tissue Barriers and Challenges in Drug Development].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain Diseases, Metabolic, I | 2019 |
Proton MRS in mild cognitive impairment.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Biomarkers; Brain; Choline; Cognitive Dysfunction; Creati | 2013 |
Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis.
Topics: Alzheimer Disease; Aspartic Acid; Brain; Creatine; Databases, Bibliographic; Humans; Magnetic Resona | 2015 |
[Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; | 2001 |
9 trials available for creatine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
3.0 T MRI arterial spin labeling and magnetic resonance spectroscopy technology in the application of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Case-Control Studies; Cerebrovascular Circulatio | 2014 |
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cholinesterase In | 2010 |
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Creatine; Double-Blind Met | 2011 |
High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cholinesterase | 2008 |
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord | 2008 |
Probable Alzheimer disease: diagnosis with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases, Metabolic; Creatine; Dementia; Diagno | 1995 |
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Topics: Acetylcholine; Alzheimer Disease; Brain; Choline; Creatine; Dose-Response Relationship, Drug; Drug A | 1997 |
96 other studies available for creatine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Relationships between frontal metabolites and Alzheimer's disease biomarkers in cognitively normal older adults.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Cognition; Creatine; Fem | 2022 |
The Auditory Afferent Pathway as a Clinical Marker of Alzheimer's Disease.
Topics: Acoustic Stimulation; Afferent Pathways; Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Cerebra | 2022 |
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition; Cognitive Dysfunction; Creatine; Glutamic Acid; H | 2022 |
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G | 2022 |
Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine
Topics: Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Brain; Cognitive Dysfunction; Creatine; De | 2020 |
Early neurotransmission impairment in non-invasive Alzheimer Disease detection.
Topics: Acetylcholine; Aged; Alzheimer Disease; Amino Acids; Biomarkers; Cognitive Dysfunction; Creatine; Fe | 2020 |
Sex-Specific Effects of Chronic Creatine Supplementation on Hippocampal-Mediated Spatial Cognition in the 3xTg Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Creatine; Dietary Supplements; Disease Models, Animal; | 2020 |
Long-Term Caloric Restriction Attenuates β-Amyloid Neuropathology and Is Accompanied by Autophagy in APPswe/PS1delta9 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animal Nutritional Physiological Phenomena; Animals; Aspar | 2021 |
Early detection of Alzheimer's disease using creatine chemical exchange saturation transfer magnetic resonance imaging.
Topics: Alzheimer Disease; Amyloidosis; Animals; Biomarkers; Cerebral Cortex; Corpus Callosum; Creatine; Dis | 2021 |
Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Angiotensin-Converting E | 2017 |
APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI study.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Brain; Creatine; | 2017 |
NSCs promote hippocampal neurogenesis, metabolic changes and synaptogenesis in APP/PS1 transgenic mice.
Topics: Alzheimer Disease; Animals; Aspartic Acid; Cognition Disorders; Creatine; Disease Models, Animal; Gl | 2017 |
Association between altered neurochemical metabolites and apathy in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Aspartic Acid; Creatine; Female; Gyrus Cinguli; | 2018 |
Topics: Adult; Alzheimer Disease; Brain; Choline; Creatine; Cross-Sectional Studies; Female; Glutamic Acid; | 2019 |
1H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Ischemia; Choline; Cogn | 2013 |
Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aspartic Acid; Biomarkers; Case-Control Studies; Cho | 2013 |
Differences in brain metabolism associated with agitation and depression in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Depression; Female; Gyrus Cinguli; Humans | 2013 |
Reduced levels of mitochondrial complex I subunit NDUFB8 and linked complex I + III oxidoreductase activity in the TgCRND8 mouse model of Alzheimer's disease.
Topics: Adenosine Triphosphate; Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cardiolip | 2014 |
Altered neurochemical metabolites in Alzheimer's disease patients with unawareness of deficits.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Awareness; Creatine; Dominance, Cerebral; | 2014 |
Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Diagnosis, Differential; Female | 2014 |
Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Arginine; Biomarkers; Carnitine; | 2014 |
Proton magnetic resonance spectroscopy in mild cognitive impairment and Alzheimer's disease: a preliminary study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2014 |
Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cholinesterase Inhibitors; Cognition Diso | 2015 |
¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Br | 2015 |
A Critical Proton MR Spectroscopy Marker of Alzheimer's Disease Early Neurodegenerative Change: Low Hippocampal NAA/Cr Ratio Impacts APOE ɛ4 Mexico City Children and Their Parents.
Topics: Adolescent; Adult; Air Pollution; Alzheimer Disease; Apolipoprotein E4; Aspartic Acid; Body Mass Ind | 2015 |
Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Depressive Disorder; Female; | 2015 |
(1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; Dominance, Cerebra | 2016 |
Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cre | 2016 |
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2008 |
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Dominance, | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
Reduced hippocampal glutamate in Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Choline; Creatine; Female; Glutamic Acid; Hi | 2011 |
Association among amyloid plaque, lipid, and creatine in hippocampus of TgCRND8 mouse model for Alzheimer disease.
Topics: Alzheimer Disease; Amino Acid Substitution; Amyloid beta-Protein Precursor; Animals; Creatine; Disea | 2010 |
Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Benzothiazoles; CA | 2010 |
Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognitive | 2011 |
Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Case-Control Studies; Choline; Cognitive Dysfunction; | 2012 |
Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; | 2011 |
Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dys | 2011 |
Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Cognitive Dysfunction; Creatine; F | 2011 |
Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (AβPP/PS1).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Cell Proliferation; Choline; C | 2012 |
Functional investigation of bilateral posterior cingulate gyri using multivoxel MR spectroscopy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognitive Dys | 2012 |
Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-tesla MR spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Disease Pr | 2012 |
Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Cholin | 2012 |
Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: a longitudinal in vivo 1 H MRS study.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Choline; Cre | 2012 |
MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspartic Acid; Biomarkers; Brain Mapping | 2013 |
Longitudinal monitoring of sex-related in vivo metabolic changes in the brain of Alzheimer's disease transgenic mouse using magnetic resonance spectroscopy.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2013 |
Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Creatine; Cystatin C; Glomerular Filtration Rate; Humans; | 2013 |
Proton magnetic resonance spectroscopy reveals similar white matter biochemical changes in patients with chronic hypertension and early Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Chronic Disease; Creatine | 2002 |
Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Case-Control Studie | 2002 |
Axonal injury within language network in primary progressive aphasia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aphasia, Primary Progressive; Aspartic Acid; Axons; Crea | 2003 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2003 |
Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy.
Topics: Adult; Aged; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Creatine; Dementia; Di | 2004 |
Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment.
Topics: Age of Onset; Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Biomarkers; Cholest | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain C | 2005 |
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Cohort Studies; Creatin | 2005 |
Evidence of biochemical and biomagnetic interactions in Alzheimer's disease: an MEG and MR spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Chemistry; Creatine; Female; Humans; Inosi | 2005 |
Proton magnetic resonance spectroscopy and magnetoencephalographic estimation of delta dipole density: a combination of techniques that may contribute to the diagnosis of Alzheimer's disease.
Topics: Acetylglucosamine; Aged; Alzheimer Disease; Brain Chemistry; Choline; Creatine; Female; Glutamic Aci | 2005 |
A comparative study of the different N-acetylaspartate measures of the medial temporal lobe in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Humans; Magnetic Resonance Spectr | 2005 |
Alzheimer's disease and proton magnetic resonance spectroscopy of limbic regions: a suggestion of a clinical-spectroscopic staging.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Animals; Aspartic Acid; Case-Contr | 2005 |
Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Biomarkers; Creatine; Crystallization; E | 2006 |
[Proton spectroscopy in Alzheimer's disease and cognitive impairment not dementia: a community study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognition | 2005 |
Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain Mapping; Cerebral Cortex; Creatine; Dementia; Down-Reg | 2006 |
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Choline; Cognition | 2007 |
Treatment monitoring and response prediction with proton MR spectroscopy in AD.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Creatine; Female; Humans; Magnetic Resonance Spectroscopy; M | 2006 |
Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E3; Aspartic Acid; Creatine; Dose-Respons | 2006 |
Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Biopsy; Brain; Cognition Disorders; Creatine; Female; Humans | 2007 |
A decrease in N-acetylaspartate and an increase in myoinositol in the anterior cingulate gyrus are associated with behavioral and psychological symptoms in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Cognition Disorders; Cre | 2007 |
Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amnesia; Aspartic Acid; Cerebral Cortex; Cognition Disorders; Creatine; Fem | 2007 |
Reproducibility of magnetic resonance spectroscopy in correlation with signal-to-noise ratio.
Topics: Aged; Alzheimer Disease; Artifacts; Aspartic Acid; Choline; Creatine; Female; Gyrus Cinguli; Humans; | 2007 |
H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases; Brain Ischemia; Case-Control Studies; | 1995 |
[1H-MR spectroscopic imaging in patients with clinically diagnosed Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Hippocampus; Humans; Lactates; Lac | 1995 |
Role of increased cerebral myo-inositol in the dementia of Down syndrome.
Topics: Adolescent; Adult; Alzheimer Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creati | 1995 |
Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Frontal Lobe; | 1995 |
Comments on use of H-1 MR spectroscopy for diagnosis of probable Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Creatine; Humans; Inositol; Magnetic Resonance Spectr | 1995 |
Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Topics: Aged; Aging; Alzheimer Disease; Aspartic Acid; Axons; Brain; Cerebral Cortex; Cerebral Ventricles; C | 1994 |
Proton magnetic resonance spectroscopy with dementia.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Creatine; Dementia; Female; Humans | 1993 |
Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Choline; Creatine; Female; Humans; Inositol | 1993 |
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Brain Ischem | 1996 |
Evaluation of automated MR spectroscopy: application in Alzheimer disease.
Topics: Adult; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Creatine; Female; Humans; Inosito | 1995 |
Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Dementia, Vascular; Diagnosis, Dif | 1996 |
Proton magnetic resonance spectroscopy in dementia of Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Female; Humans; | 1997 |
Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Artifacts; Aspartic Acid; Brain Chemistry; Choline; Crea | 1998 |
[Clinical uses of proton magnetic resonance spectroscopy of the brain].
Topics: AIDS Dementia Complex; Alzheimer Disease; Animals; Aspartic Acid; Brain; Brain Diseases; Brain Disea | 1998 |
Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Mapping; Choline; Creatine; Female; Humans; Ino | 1998 |
In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Cerebral Cortex; Choline; Creatine; Female; Humans; Mag | 1999 |
ATP nucleotidylation of creatine kinase.
Topics: Adenosine Triphosphate; Alzheimer Disease; Animals; Azides; Brain Chemistry; Chromatography, High Pr | 1999 |
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde | 2000 |
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cognitio | 2001 |
Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Choline; Cre | 2001 |
Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Cognition Disorders; Creatine; Cross-Sectional Studies; Fema | 2001 |
MRI white matter hyperintensities, (1)H-MR spectroscopy and cognitive function in geriatric depression: a comparison of early- and late-onset cases.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Depressive Disorder, Major; Energy | 2001 |
Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Creatine; Female; Glutamic Acid; Glutamine; Humans; M | 2002 |
Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Female; Hippocampus; Humans; Magnetic Res | 2002 |